Casdatifan + Cabozantinib + Placebo
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 41/100
41
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Clear Cell Renal Cell Carcinoma
Conditions
Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
Trial Timeline
Sep 8, 2025 → Dec 1, 2030
NCT ID
NCT07011719About Casdatifan + Cabozantinib + Placebo
Casdatifan + Cabozantinib + Placebo is a phase 3 stage product being developed by Arcus Biosciences for Metastatic Clear Cell Renal Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07011719. Target conditions include Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Clear Cell Renal Cell Carcinoma were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
17
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07011719 | Phase 3 | Recruiting |
Competing Products
20 competing products in Metastatic Clear Cell Renal Cell Carcinoma